290 ‒ Liquid biopsies for early cancer detection, the role of epigenetics in aging, and the more

View show notes here: https://bit.ly/4bHY6wS Become a member to receive exclusive content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Alex Aravanis is a leader in research and development of technologies and clinical tests utilizing the latest tools in DNA analysis and data science. In this episode, Alex delves into two interconnected topics: liquid biopsies and epigenetics. He begins by tracing the trajectory of genome sequencing and tumor sequencing, setting the stage for a detailed exploration of liquid biopsies as an early cancer detection method. The discussion encompasses key concepts such as cell-free DNA, DNA methylation, sensitivity, specificity, and the predictive values associated with liquid biopsies. Transitioning to epigenetics, Alex examines the intricate interplay of DNA methylation and aging biology and explores the possibility of using cellular reprogramming to reverse epigenetic changes that occur with aging. We discuss: 0:00:00 - Intro 0:00:08 - Alex’s background in applying engineering to problems in medicine 0:19:57 - A primer on human genetics, and the history and current landscape of DNA sequencing 0:24:05 - The advent and evolution of liquid biopsies for early detection of cancer 0:44:14 - The role of cell-free DNA in cancer detection: how incidental findings in non-invasive prenatal testing led to the development of liquid biopsies 0:51:05 - The development of a universal blood test for cancer detection and a discussion of specificity of tests 0:56:48 - Advancements in cell-free DNA analysis and development of a multi-cancer screening test at GRAIL 1:05:27 - DNA methylation explained 1:11:00 - Optimizing cancer detection with methylation analysis of cfDNA in small blood samples 1:17:22 - The importance of understanding sensitivity, specificity, positive predictive value, and negative predictive value in cancer screening 1:32:57 - The performance of the GRAIL Galleri test and its ability to detect various types and stages of cancer 1:41:05 - Do early cancer detection methods, like liquid biopsies, translate to improvement in overall survival? 1:54:45 - The role of epigenetics in aging 2:01:58 - How cell-free DNA methylation patterns can help identify a cancer’s tissue of origin 2:09:48 - Cellular and epigenetic reprogramming and other exciting work in the field of aging -------- About: The Peter Attia Drive is a deep-dive podcast focusing on maximizing longevity, and all that goes into that from physical to cognitive to emotional health. With over 70 million episodes downloaded, it features topics including exercise, nutritional biochemistry, cardiovascular disease, Alzheimer’s disease, cancer, mental health, and much more. Peter Attia is the founder of Early Medical, a medical practice that applies the principles of Medicine 3.0 to patients with the goal of lengthening their lifespan and simultaneously improving their healthspan. Learn more: https://peterattiamd.com Connect with Peter on: Facebook: http://bit.ly/PeterAttiaMDFB Twitter: http://bit.ly/PeterAttiaMDTW Instagram: http://bit.ly/PeterAttiaMDIG Subscribe to The Drive: Apple Podcast: http://bit.ly/TheDriveApplePodcasts Overcast: http://bit.ly/TheDriveOvercast Spotify: http://bit.ly/TheDriveSpotify Google Podcasts: http://bit.ly/TheDriveGoogle Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies. For a full list of our registered and unregistered trademarks, trade names, and service marks, please review our Terms of Use: https://peterattiamd.com/terms-of-use/